TScan Therapeutics launched Wednesday with $48 million, a star-studded management team and T-cell receptor (TCR) technology out of Harvard University. The company aims to uncover new targets for ...

Medigene’s focus is developing cell therapies from a patient’s own cells, engineering them with a T cell receptor (TCR) that targets an antigen on a cancer cell. Under the deal announced Tuesday, the ...

Bluebird bio has added two targets and up to €417 million ($500 million) in milestones to its T-cell receptor (TCR) collaboration with Medigene. The expanded deal tasks Medigene with applying its TCR ...

Kite, a Gilead Company, and Gadeta B.V., a privately-held company focused on the discovery and development of novel cancer immunotherapies based on gamma delta T cell receptors (TCRs), have entered ...

bluebird bio will use Gritstone Oncology’s artificial intelligence (AI) platform to research, develop, and commercialize T-cell receptor (TCR) directed cell therapies for cancer, under a collaboration ...

Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid ...

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...